Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Zanaga Iron Ore

    MCap

    GBP79m

    Last close

    GBP0.09

    ▲ 2.09 (28.51%)

    Cadence Minerals

    MCap

    GBP20m

    Last close

    GBP0.05

    ▲ 0.80 (20.25%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) on-track with registrational Tedopi trial
Published by Arron Aatkar, PhD

OSE Immunotherapeutics has received a positive recommendation from the independent data monitoring committee (IDMC) to continue the ARTEMIA programme without any modifications. This is the registrational Phase III trial evaluating OSE’s lead cancer vaccine, Tedopi, in non-small cell lung cancer (NSCLC). A second IDMC review is expected in Q126, and management then anticipates completing patient recruitment by end-2026, before a primary endpoint readout in Q128.

ARTEMIA (which commenced in September 2024) is investigating Tedopi as a potential second-line monotherapy for NSCLC, after the use of immune checkpoint inhibitors as first-line treatments. The trial has been designed to randomise participants (expected n=363) 2:1 to receive either Tedopi or docetaxel (standard of care in the second-line setting).

Next Sparks Commentary in this sector >

Latest

TMT | Comment

Cordel (AIM: CRDL) wins V/Line railway contract

Consumer | Comment

The Platform Group (FRA: TPG) – ambitious FY30 growth targets

TMT | Comment

Kainos (LSE: KNOS) reports positive H126

Consumer | Comment

Global Fashion Group (DUS: GFG) – positive adjusted EBITDA over last 12 months

Consumer | Comment

Victoria (LSE:VCP) – higher EBITDA in H126